Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET
Company Participants
Ian Karp - SVP, IR and Corporate Communications
John Leonard - President and CEO
David Lebwohl - EVP and CMO
Laura Sepp-Lorenzino - EVP and CSO
Glenn Goddard - EVP and CFO
Conference Call Participants
Maury Raycroft - Jefferies
Unidentified Analyst - RBC Capital
Joseph Thome - TD Cowen
Mary Kate - Bank of America
Unidentified Analyst - Truist Securities
Unidentified Analyst - Barclays
Debjit Chattopadhyay - Guggenheim Partners
Yanan Zhu - Wells Fargo Securities
Dae Gon Ha - Stifel
Myles Minter - William Blair
Sung Yoon - J.P. Morgan
William Pickering - Bernstein
Rick Bienkowski - Cantor Fitzgerald
Jay Olson - Oppenheimer
Silvan Tuerkcan - JMP Securities
Unidentified Analyst - Raymond James
Unidentified Analyst - Goldman Sachs
Richard Law - Credit Suisse
Operator
Good morning and welcome to the Intellia Therapeutics' Second Quarter 2023 Earnings Conference Call. My name is Drew and I will be your conference operator today. Following formal remarks, we will open the call up for a question-and-answer session. This conference is being recorded at the Company's request and will be available on the Company's website following the end of the call. As a reminder, all participants are currently in a listen-only mode. [Operator Instructions]. I will now turn the conference over to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.
Ian Karp
Thank you, operator and good morning, everyone. Welcome to Intellia Therapeutics second quarter 2023 earnings call. Earlier this morning, Intellia issued a press release outlining the Company's progress this quarter, as well as topics for discussion on today's call. This release can be found on the Investors & Media section of Intellia's website at intelliatx.com. This call is being broadcast live and a replay will be archived on the Company's website.
At this time, I would like to take a minute to remind listeners that during this call, Intellia management may make certain forward-looking statements and ask that you refer to our SEC filings available at sec.gov for a discussion of potential risks and uncertainties. All information presented on this call is current as of today, and Intellia undertakes no duty to update this information unless required by law.
Joining me from Intellia are Dr. John Leonard, Chief Executive Officer; Dr. David Lebwohl, Chief Medical Officer; and Dr. Laura Sepp-Lorenzino, Chief Scientific Officer; and Glenn Goddard, Chief Financial Officer. John will begin with an overview of recent business highlights. David will provide an update on our clinical programs, Laura will review our R&D progress, and Glenn will review Intellia’s financial results for the second quarter 2023 before we open up the call for your Q&A.